Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
Neuroblastoma: A rare pediatric cancer of the nervous system that usually starts on the glands above the kidney and can spread to the abdomen, spine, chest, neck, or pelvis.
Central Nervous System (CNS)/Leptomeningeal Metastases (LM): This condition occurs when cancer spreads to the membranes lining the brain and spinal cord. This can result from many types of cancer, including neuroblastoma.
Osteosarcoma: A cancer that starts in the bones and often develops around the knee or the upper arm.
Diffuse Intrinsic Pontine Glioma (DIPG): A highly aggressive and difficult-to-treat tumor found at the base of the brain.
Medulloblastoma: A type of cancer that starts in the lowest back part of the brain (the cerebellum). Although rare, it is the most common cancerous brain tumor found in children.
Desmoplastic Small Round Cell Tumor (DSRCT): A rare tumor that is usually located in the abdomen.Learn more
Antibody immunotherapy is a type of treatment that’s designed to target specific antigens (molecules that stimulate an immune response) in the body and neutralize them. In early and ongoing clinical trials, the antibodies developed by Y-mAbs have shown results that garner continued evaluation.Learn more
Y-mAbs was founded by Thomas Gad, President and Head of Business Development and Strategy, who is also the father of a high-risk neuroblastoma survivor.
After years of searching for an effective option for neuroblastoma, Gad's daughter received treatment from Memorial Sloan Kettering Cancer Center (MSKCC). Since then, Gad has envisioned helping other patients and families get access to the same products.
Y-mAbs may someday help patients fight cancer with their advanced pipeline of antibody immunotherapies, which are currently being investigated in ongoing clinical trials.
Pediatric cancer has long been a challenge for the medical profession. With years of growing knowledge and insights, treatment advancements are being made through research.
Y-mAbs is working to develop targeted approaches to treating rare and challenging pediatric cancers with the hope of extending survival and helping with safety concerns.
Y-mAbs Therapeutics, Inc. (Y-mAbs), is a state-of-the-art, late-stage clinical, global biopharmaceutical company that is focused on the research and development of innovative antibody-based products under investigation using a range of cutting-edge technologies, licensed from one of the largest and most prestigious cancer-care establishments in the world—MSKCC.
With its robust pipeline, Y-mAbs is committed to becoming a world leader in creating pediatric-based oncology treatments.